01 / Vendor Profile
GRIFOLS THERAPEUTICS LLC Federal Contracts and Awards
UEI UFQ3A7GKJ5C7 · CAGE 6SLC6
Federal contract activity attributed to this vendor identity across FY 2020–FY 2026. Obligations are FPDS accounting transactions, not company revenue.
02 / Federal Business Size
Federal contract market at a glance
Measured consistently across FY 2020–FY 2026.
Across FY 2020–FY 2026, FPDS records attribute $2.55M in net contract obligations to GRIFOLS THERAPEUTICS LLC across 49 contract actions. Net obligations include positive obligations and later deobligations recorded during the same period.
03 / Spending Trend
GRIFOLS THERAPEUTICS LLC contract spending by year
Annual net obligations show whether recorded federal business expanded or contracted, while actions and customer counts show the breadth of that activity.
Total obligations$0
FY 2025ObligationsHistorical spending range
| Fiscal year | Obligations | Actions | Federal customers | Change |
|---|---|---|---|---|
| FY 2020 | $737.4K | 28 | 3 | — |
| FY 2021 | $824.7K | 13 | 2 | +11.8% |
| FY 2022 | $457.3K | 4 | 1 | −44.5% |
| FY 2023 | -$83.3K | 2 | 1 | −118.2% |
| FY 2024 | $613.2K | 1 | 1 | +836.0% |
| FY 2025 | $0 | 1 | 1 | −100.0% |
04 / Federal Customers
Which federal agencies buy from GRIFOLS THERAPEUTICS LLC?
Ranked by net obligations during FY 2020–FY 2026.
| Agency | Code | Obligations | Actions | Vendor share |
|---|---|---|---|---|
| 3600 | $1.86M | 41 | 72.8% | |
| 7505 | $613.2K | 2 | 24.1% | |
| 7570 | $77.6K | 5 | 3.0% | |
| 97AS | $1.3K | 1 | 0.1% |
05 / Contracting Offices
Which contracting offices buy from GRIFOLS THERAPEUTICS LLC?
Ranked by net obligations during FY 2020–FY 2026.
| Office | Code | Agency | Obligations | Actions | Vendor share |
|---|---|---|---|---|---|
| 36C260 | VETERANS AFFAIRS, DEPARTMENT OF | $1.66M | 18 | 64.9% | |
| 75A501 | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE | $613.2K | 2 | 24.1% | |
| 36C262 | VETERANS AFFAIRS, DEPARTMENT OF | $250.8K | 3 | 9.8% | |
| 36C241 | VETERANS AFFAIRS, DEPARTMENT OF | $111.8K | 4 | 4.4% | |
| 36C249 | VETERANS AFFAIRS, DEPARTMENT OF | $109.7K | 8 | 4.3% | |
| 75P002 | OFFICE OF THE ASSISTANT SECRETARY FOR ADMINISTRATION (ASA) | $77.6K | 5 | 3.0% | |
| 36C245 | VETERANS AFFAIRS, DEPARTMENT OF | $10.8K | 2 | 0.4% | |
| 36C242 | VETERANS AFFAIRS, DEPARTMENT OF | $8.4K | 1 | 0.3% | |
| SPE2DP | DEFENSE LOGISTICS AGENCY | $1.3K | 1 | 0.1% | |
| 36C263 | VETERANS AFFAIRS, DEPARTMENT OF | -$46 | 1 | 0.0% |
06 / Top NAICS Industries
Which industries define this vendor’s federal work?
07 / Top Product and Service Codes
What products and services does the government buy from this vendor?
08 / Competition Pattern
How was GRIFOLS THERAPEUTICS LLC’s federal work competed?
Competition categories describe the procurement path recorded on the underlying contract actions.
09 / Recent Contract Awards
What contract actions were recorded most recently for GRIFOLS THERAPEUTICS LLC?
The latest recorded PIIDs connect this profile to the underlying federal award search.
| Award / PIID | Signed | Obligation | Agency / office | NAICS | PSC |
|---|---|---|---|---|---|
| 75A50124C00050 | Aug 6, 2025 | $0 | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE BARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | AN13 |
10 / Interpreting the Profile
How should you evaluate GRIFOLS THERAPEUTICS LLC as a federal contractor?
Read obligations, customers, markets, competition, and individual awards together. A large historical total indicates federal scale, but it does not by itself describe current backlog, commercial revenue, profitability, or future opportunity.
Separate obligations from revenue
FPDS obligations are government accounting actions and may include later deobligations.
Follow customer concentration
Agency and office concentration reveals where the vendor’s federal relationships are strongest.
Test market overlap
NAICS and PSC shares show whether the vendor competes in the same markets as your company.
Inspect the awards
Open the PIIDs to verify dates, offices, classifications, and transaction history.